Lurie Cancer Center and Northwestern Medicine Experts Present at #ASH23
Physicians and scientists from the Robert H. Lurie Comprehensive Cancer Center of Northwestern University and Northwestern Medicine will present and discuss exciting new research and important clinical findings at the American Society of Hematology (ASH) Annual Meeting, December 9-12 in San Diego, California. With more than 18,000 members from nearly 100 countries, ASH is the world’s largest professional society serving both clinicians and scientists around the world who are working to conquer blood diseases.
Follow @LurieCancer and use #ASH23 to follow and share on Twitter.
Presenting authors and investigators who will be leading sessions at #ASH23 include the following. View the full 2023 ASH Annual Meeting Schedule.
Friday, December 8 |
---|
Scientific Workshop on Germline Predisposition to Hematopoietic Malignancies and Bone Marrow Failure Program |
Saturday, December 9 |
Immune Reconstitution and Infection Patterns Following CAR T-Cell Therapy in Patients with Aggressive Lymphoma |
Exploration of Language As a Barrier to the Assessment and Management of CAR T-Cell Therapy Associated Toxicities |
Aggressive Lymphomas: Clinical and Epidemiological: Poster I |
Sunday, December 10 |
Abstract No. 626 |
Bone Marrow Failure: Acquired: Unraveling the Future of PNH Therapy From Clinical Trials |
Abstract No. 2825 |
Characteristics and Outcomes of Younger Adult Patients (Pts) with Myelodysplastic Syndromes (MDS): A Multicenter Retrospective Study |
Rapid Degradation of mDia2 Protein during Terminal Erythropoiesis Via an In Vivo Aid System: An Alternative Approach for Loss-of-Function Studies |
Monday, December 11 |
Naturally Occurring Mutations in Human T Cell Lymphomas Enhance Engineered T Cell Therapies |
Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Improving Intensive Chemotherapy Regimens for Treatment of AML |
Abstract No. 949 |
A Phase Ib Study to Evaluate the Safety and Efficacy of Nivolumab in Combination with R-CHOP in High-Risk DLBCL |
NOTE: Presenter information is sometimes incomplete. If your session is missing, please email the link to cancer@northwestern.edu.